Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder

Agin-Liebes GI Malone T Yalch MM , et al. (2020) Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol 34: 155–166.

Anderson CB Carter FA McIntosh VV , et al. (2002) Self-harm and suicide attempts in individuals with bulimia nervosa. Eat Disord 10: 227–243.

Andries A Frystyk J Flyvbjerg A , et al. (2014) Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial. Int J Eat Disord 47: 18–23.

Audenaert K Van Laere K Dumont F , et al. (2003) Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nucl Med 44: 163–169.

Bailer UF Frank GK Henry SE , et al. (2005) Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [carbonyl11C]WAY-100635. Arch Gen Psychiatry 62: 1032–1041.

Bailer UF Price JC Meltzer CC , et al. (2004) Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: Relationships to harm avoidance and drive for thinness. Neuropsychopharmacology 29: 1143–1155.

Berkman ND Lohr KN Bulik CM (2007) Outcomes of eating disorders: a systematic review of the literature. Int J Eat Disord 40: 293–309.

Brewerton TD Wang JB Lafrance A , et al. (2022) MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. J Psychiatr Res 149: 128–135.

Buhlmann U Etcoff NL Wilhelm S (2006) Emotion recognition bias for contempt and anger in body dysmorphic disorder. J Psychiatr Res 40: 105–111.

Buhlmann U McNally RJ Etcoff NL , et al. (2004) Emotion recognition deficits in body dysmorphic disorder. J Psychiatr Res 38: 201–206.

Carhart-Harris R Giribaldi B Watts R , et al. (2021) Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 384: 1402–1411.

Carhart-Harris RL Erritzoe D Williams T , et al. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109: 2138–2143.

Davis AK Barrett FS May DG , et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 78: 481–489.

Daws RE Timmermann C Giribaldi B , et al. (2022) Increased global integration in the brain after psilocybin therapy for depression. Nat Med 28: 844–851.

Doss MK Považan M Rosenberg MD , et al. (2021) Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry 11: 574.

Dyck RH Cynader MS (1993) Autoradiographic localization of serotonin receptor subtypes in cat visual cortex: Transient regional, laminar, and columnar distributions during postnatal development. J Neurosci 13: 4316–4338.

Feusner JD Bystritsky A Hellemann G , et al. (2010) Impaired identity recognition of faces with emotional expressions in body dysmorphic disorder. Psychiatry Res 179: 318–323.

Feusner JD Hembacher E Moller H , et al. (2011) Abnormalities of object visual processing in body dysmorphic disorder. Psychol Med 41: 2385–2397.

Foldi CJ Liknaitzky P Williams M , et al. (2020) Rethinking therapeutic strategies for anorexia nervosa: insights from psychedelic medicine and animal models. Front Neurosci 14: 43.

Frank GK Kaye WH Meltzer CC , et al. (2002) Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry 52: 896–906.

Gable RS (2004) Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 99: 686–696.

Galusca B Costes N Zito NG , et al. (2008) Organic background of restrictive-type anorexia nervosa suggested by increased serotonin 1A receptor binding in right frontotemporal cortex of both lean and recovered patients: [18F]MPPF PET scan study. Biol Psychiatry 64: 1009–1013.

Galvão-Coelho NL Marx W Gonzalez M , et al. (2021) Classic serotonergic psychedelics for mood and depressive symptoms: A meta-analysis of mood disorder patients and healthy participants. Psychopharmacology (Berl) 238: 341–354.

Gerstl F Windischberger C Mitterhauser M , et al. (2008) Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. Neuroimage 41: 204–211.

Grant JE Kim SW Eckert ED (2002) Body dysmorphic disorder in patients with anorexia nervosa: Prevalence, clinical features, and delusionality of body image. Int J Eat Disord 32: 291–300.

Griffiths RR Johnson MW Carducci MA , et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 30: 1181–1197.

Grob CS Danforth AL Chopra GS , et al. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68: 71–78.

Hanes KR (1996) Serotonin, psilocybin, and body dysmorphic disorder: A case report. J Clin Psychopharmacol 16: 188–189.

Harding F Seynaeve M Keeler J , et al. (2021) Perspectives on psychedelic treatment and research in eating disorders: A web-based questionnaire study of people with eating disorders. J Integr Neurosci 20: 551–560.

Ho JT Preller KH Lenggenhager B (2020) Neuropharmacological modulation of the aberrant bodily self through psychedelics. Neurosci Biobehav Rev 108: 526–541.

Horowitz MJ (1969) Flashbacks: Recurrent intrusive images after the use of LSD. Am J Psychiatry 126: 565–569.

Johansen P Krebs TS (2015) Psychedelics not linked to mental health problems or suicidal behavior: A population study. J Psychopharmacol 29: 270–279.

Johnson M Richards W Griffiths R (2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol 22: 603–620.

Kaye WH Frank GK Meltzer CC , et al. (2001) Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa. Am J Psychiatry 158: 1152–1155.

Keegan E Tchanturia K Wade TD (2021) Central coherence and set-shifting between nonunderweight eating disorders and anorexia nervosa: A systematic review and meta-analysis. Int J Eat Disord 54: 229–243.

Khalsa SS Portnoff LC McCurdy-McKinnon D , et al. (2017) What happens after treatment? A systematic review of relapse, remission, and recovery in anorexia nervosa. J Eat Disord 5: 20.

Koch K Reeß TJ Rus OG , et al. (2018) Increased default mode network connectivity in obsessive-compulsive disorder during reward processing. Front Psychiatry 9: 254.

Kometer M Schmidt A Jäncke L , et al. (2013) Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci 33: 10544–10551.

Krebs TS Johansen P (2013) Psychedelics and mental health: A population study. PLoS One 8: e63972.

Lafrance A Loizaga-Velder A Fletcher J , et al. (2017) Nourishing the spirit: Exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders. J Psychoactive Drugs 49: 427–435.

Lafrance A Strahan E Bird BM , et al. (2021) Classic psychedelic use and mechanisms of mental health: Exploring the mediating roles of spirituality and emotion processing on symptoms of anxiety, depressed mood, and disordered eating in a community sample. J Humanist Psychol. Advance online publication. https://doi.org/10.1177/00221678211048049

Larsen JK (2016) Neurotoxicity and LSD treatment: A follow-up study of 151 patients in Denmark. Hist Psychiatry 27: 172–189.

Larsen JK (2017) LSD treatment in Scandinavia: Emphasizing indications and short-term treatment outcomes of 151 patients in Denmark. Nord J Psychiatry 71: 489–495.

Lee S Ran Kim K Ku J , et al. (2014) Resting-state synchrony between anterior cingulate cortex and precuneus relates to body shape concern in anorexia nervosa and bulimia nervosa. Psychiatry Res 221: 43–48.

Leonard HL Rapoport JL (1987) Relief of obsessive-compulsive symptoms by LSD and psilocin. Am J Psychiatry 144: 1239–1240.

Linardon J Wade TD (2018) How many individuals achieve symptom abstinence following psychological treatments for bulimia nervosa? A meta-analytic review. Int J Eat Disord 51: 287–294.

Lipsman N Lam E Volpini M , et al. (2017) Deep brain stimulation of the subcallosal cingulate for treatment-refractory anorexia nervosa: 1 year follow-up of an open-label trial. Lancet Psychiatry 4: 285–294.

Lipsman N Woodside DB Giacobbe P , et al. (2013) Subcallosal cingulate deep brain stimulation for treatment-refractory anorexia nervosa: A phase 1 pilot trial. Lancet 381: 1361–1370.

Lugo-Radillo A Md Cortes-Lopez JM (2021) Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. J Psychoactive Drugs 53: 146–148.

Malcolm A Labuschagne I Castle D , et al. (2018) The relationship between body dysmorphic disorder and obsessive-compulsive disorder: A systematic review of direct comparative studies. Aust N Z J Psychiatry 52: 1030–1049.

Masters R Houston J (2000) The varieties of psychedelic experience: The classic guide to the effects of LSD on the human psyche. South Paris, Maine: Park Street Press.

Matsushima Y Shirota O Kikura-Hanajiri R , et al. (2009) Effects of Psilocybe argentipes on marble-burying behavior in mice. Biosci Biotechnol Biochem 73: 1866–1868.

McClelland J Kekic M Campbell IC , et al. (2016) Repetitive transcranial magnetic stimulation (rTMS) treatment in enduring anorexia nervosa: A case series. Eur Eat Disord Rev 24: 157–163.

Miyake A Friedman NP Emerson MJ , et al. (2000) The unity and diversity of executive functions and their contributions to complex “Frontal Lobe” tasks: A latent variable analysis. Cogn Psychol 41: 49–100.

Moreau AW Amar M Le Roux N , et al. (2010) Serotoninergic fine-tuning of the excitation-inhibition balance in rat visual cortical networks. Cereb Cortex 20: 456–467.

Moreno FA Delgado PL (1997) Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry 154: 1037–1038.

Moreno FA Wiegand CB Taitano EK , et al. (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67: 1735–1740.

Müller F Kraus E Holze F , et al. (2022) Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. Psychopharmacology (Berl) 239: 1933–1943.

Murphy-Beiner A Soar K (2020) Ayahuasca’s ‘afterglow’: Improved mindfulness and cognitive flexibility in ayahuasca drinkers. Psychopharmacology (Berl) 237: 1161–1169.

Murray SB Strober M Tadayonnejad R , et al. (2022) Neurosurgery and neuromodulation for anorexia nervosa in the 21st century: A systematic review of treatment outcomes. Eat Disord 30: 26–53.

Nichols DE Walter H (2021) The history of psychedelics in psychiatry. Pharmacopsychiatry 54: 151–166.

Noorani T Garcia-Romeu A Swift TC , et al. (2018) Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. J Psychopharmacol 32: 756–769.

Nutt D Erritzoe D Carhart-Harris R (2020) Psychedelic psychiatry’s brave new world. Cell 181: 24–28.

Odland AU Kristensen JL Andreasen JT (2021) Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice. Behav Brain Res 401: 113093.

Palhano-Fontes F Andrade KC Tofoli LF , et al. (2015) The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One 10: e0118143.

Pavan C Simonato P Marini M , et al. (2008) Psychopathologic aspects of body dysmorphic disorder: A literature review. Aesthetic Plast Surg 32: 473–484.

Phillipou A Castle DJ Rossell SL (2019) Direct comparisons of anorexia nervosa and body dysmorphic disorder: A systematic review. Psychiatry Res 274: 129–137.

Pisetsky EM Thornton LM Lichtenstein P , et al. (2013) Suicide attempts in women with eating disorders. J Abnorm Psychol 122: 1042–1056.

Pollatos O Herbert BM Schandry R , et al. (2008) Impaired central processing of emotional faces in anorexia nervosa. Psychosom Med 70: 701–708.

Rabe-Jablonska Jolanta J Sobow Tomasz M (2000) The links between body dysmorphic disorder and eating disorders. Eur Psychiatry 15: 302–305.

Rangaprakash D Bohon C Lawrence KE , et al. (2018) Aberrant dynamic connectivity for fear processing in anorexia nervosa and body dysmorphic disorder. Front Psychiatry 9: 273.

Reiff CM Richman EE Nemeroff CB , et al. (2020) Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry 177: 391–410.

Renelli M Fletcher J Tupper KW , et al. (2020) An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eat Weight Disord 25: 437–444.

Ricca V Nacmias B Cellini E , et al. (2002) 5-HT2A receptor gene polymorphism and eating disorders. Neurosci Lett 323: 105–108.

Riva G (2012) Neuroscience and eating disorders: The allocentric lock hypothesis. Med Hypotheses 78: 254–257.

Riva G Gaudio S (2018) Locked to a wrong body: Eating disorders as the outcome of a primary disturbance in multisensory body integration. Conscious Cogn 59: 57–59.

Roseman L Haijen E Idialu-Ikato K , et al. (2019) Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. J Psychopharmacol 33: 1076–1087.

Rößner A Juniak I van Noort BM , et al. (2017) Cognitive flexibility in juvenile anorexia nervosain relation to comorbid symptoms of depression, obsessive compulsive symptoms and duration of illness. Z Kinder Jugendpsychiatr Psychother 45: 371–380.

Savage C (1955) Variations in ego feeling induced by D-lysergic acid diethylamide (LSD-25). Psychoanal Rev 42: 1–16.

Scharner S Stengel A (2021) Animal models for anorexia nervosa—a systematic review. Front Hum Neurosci 14: 596381.

Schmidt U Campbell IC (2013) Treatment of eating disorders can not remain ‘brainless’: The case for brain-directed treatments. Eur Eat Disord Rev 21: 425–427.

Sheline YI Barch DM Price JL , et al. (2009) The default mode network and self-referential processes in depression. Proc Natl Acad Sci U S A 106: 1942–1947.

Singh AR Veale D (2019) Understanding and treating body dysmorphic disorder. Indian J Psychiatry 61: S131–S135.

Sorbi S Nacmias B Tedde A , et al. (1998) 5-HT2A promoter polymorphism in anorexia nervosa. Lancet 351: 1785.

Spreng RN Mar RA Kim AS (2009) The common neural basis of autobiographical memory, prospection, navigation, theory of mind, and the default mode: a quantitative meta-analysis. J Cogn Neurosci 21: 489–510.

Spriggs MJ Douglass HM Park RJ , et al. (2021a) Study protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A pilot study”. Front Psychiatry 12: 735523.

Spriggs MJ Kettner H Carhart-Harris RL (2021b) Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat Weight Disord-Studies on Anorexia Bulimia and Obesity 26: 1265–1270.

Stern ER Fitzgerald KD Welsh RC , et al. (2012) Resting-state functional connectivity between fronto-parietal and default mode networks in obsessive-compulsive disorder. PLoS One 7: e36356.

Steward T Menchon JM Jiménez-Murcia S , et al. (2018) Neural network alterations across eating disorders: A narrative review of fMRI studies. Curr Neuropharmacol 16: 1150–1163.

Stroud JB Freeman TP Leech R , et al. (2018) Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology (Berl) 235: 459–466.

Stuhrmann A Suslow T Dannlowski U (2011) Facial emotion processing in major depression: A systematic review of neuroimaging findings. Biol Mood Anxiety Disord 1: 10.

Thompson-Brenner H (2016) Improving psychotherapy for anorexia nervosa: Introduction to the special section on innovative treatment approaches. Psychotherapy (Chic) 53: 220–222.

Tiihonen J Keski-Rahkonen A Löppönen M , et al. (2004) Brain serotonin 1A receptor binding in bulimia nervosa. Biol Psychiatry 55: 871–873.

van Amsterdam J Opperhuizen A van den Brink W (2011) Harm potential of magic mushroom use: A review. Regul Toxicol Pharmacol 59: 423–429.

Van den Eynde F Guillaume S Broadbent H , et al. (2013) Repetitive transcranial magnetic stimulation in anorexia nervosa: A pilot study. Eur Psychiatry 28: 98–101.

Verroust V Zafar R Spriggs MJ (2021) Psilocybin in the treatment of anorexia nervosa: The English transition of a French 1959 case study. Annales Medico-Psychologiques 179: 777–781.

Vollenweider FX Preller KH (2020) Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci 21: 611–624.

Walitza S Wewetzer C Warnke A , et al. (2002) 5-HT2A promoter polymorphism -1438G/A in children and adolescents with obsessive-compulsive disorders. Mol Psychiatry 7: 1054–1057.

Watakabe A Komatsu Y Sadakane O , et al. (2009) Enriched expression of serotonin 1B and 2A receptor genes in macaque visual cortex and their bidirectional modulatory effects on neuronal responses. Cereb Cortex 19: 1915–1928.

Watts R Day C Krzanowski J , et al. (2017) Patients’ accounts of increased “Connectedness” and “Acceptance” after psilocybin for treatment-resistant depression. J Humanist Psychol 57: 520–564.

Wilcox JA (2014) Psilocybin and obsessive compulsive disorder. J Psychoactive Drugs 46: 393–395.

Zeifman RJ Wagner AC Watts R , et al. (2020) Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Front Psychiatry 11: 782.

Zhang S Chen JM Kuang L , et al. (2016) Association between abnormal default mode network activity and suicidality in depressed adolescents. BMC Psychiatry 16: 337.